Justification Notice for Award to Pfizer Inc.
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- RequestOS264667
- Agency
- Office of the Assistant Secretary for Preparedness and Response Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50120C00194 Federal contract award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Place of performance
- USA
Notice details come from SAM.gov. Updated .
About this opportunity
This class justification and approval from the Department of Health and Human Services provides the legal basis for limiting competition and awarding sole source contracts to address the COVID-19 pandemic. The agency requires pharmaceuticals including hydromorphone, cisatracurium, zosyn, cefepime, dobutamine, ondansetron, dopamine, and heparin with an estimated total value of $30 billion for response and recovery efforts through December 2021. On September 25, 2020, an unknown contract for an unknown amount was awarded to an unknown vendor to supply these products immediately due to the urgent need to procure supplies and services for containment and mitigation of this public health emergency, as declared by Presidential Proclamation on March 13, 2020.
Notice text
This is a class Justification & Approval (J&A) in accordance with FAR § 6.303-1(d) and 6.302-2, Unusual and Compelling Urgency, FAR § 8.405-6(a)(1)(A), Limiting Sources, and FAR § 16.505(b)(2)(i)(A), Exceptions to the Fair Opportunity Process for all contract actions to facilitate the recovery efforts necessary to address the 2019 Novel Coronavirus (COVID-19). Because COVID-19 is an emerging disease, and there are no vaccines or approved treatments, it is prudent to have adequate flexibility to address this public health emergency. This class J&A is essential to respond to urgent requests for immediate support to respond to the expanding outbreak of COVID-19 which was just declared a pandemic on March 11, 2020 and a national emergency via Presidential Proclamation on March 13, 2020. This class J&A supersedes all other class J&A’s executed and issued by HHS and negates the need for individual J&As for contract actions to facilitate the recovery efforts necessary to address COVID-19.
The mission to respond to the community spread of COVID-19 throughout the United States and the mission to repatriate individuals who have been exposed to the virus are both ongoing and growing. The COVID-19 outbreak has evolved at a fast pace, resulting in an urgent and compelling need to rapidly procure supplies and services to support the containment and recovery of the outbreak throughout the country and world. This
constitutes an unusual and compelling urgency that demands immediate attention. Immediate acquisition of services and supplies will help ensure that the United States of America remains prepared for and capable of responding to a public health emergency in the necessary and immediate manner that is required. There is a
need for Hydromorphone, Cisatracurium, Zosyn, Cefepime, Dobutamine, Ondansetron, Dopamine, and Heparin.
Awarded contract 75A50120C00194 to unknown vendor for unknown amount on 2020-09-25.
Attachments
| File | Type | Posted |
|---|---|---|
| Class J and A.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Justification Notice for Award to Pfizer Inc. | Limited / Sole Source Justification | |
| Award Notice to Pfizer Inc. | Award Notice |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity